国: カナダ
言語: 英語
ソース: Health Canada
CHLORHEXIDINE GLUCONATE
XTTRIUM LABORATORIES INC.
A01AB03
CHLORHEXIDINE
0.12%
LIQUID
CHLORHEXIDINE GLUCONATE 0.12%
ORAL
15ML/473ML
Prescription
MISCELLANEOUS ANTI-INFECTIVES
Active ingredient group (AIG) number: 0107629007; AHFS:
APPROVED
2014-10-10
_ _ _ _ _Page 1 of 19_ PRODUCT MONOGRAPH CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP Chlorhexidine Gluconate 0.12% Oral Rinse Liquid, 0.12% Chlorhexidine Gluconate Antigingivital Oral Rinse Xttrium Laboratories, Inc. 1200 East Business Center Drive Mount Prospect, IL 60056 USA Date of Preparation: October 09, 2014 Submission Control No: 168915 _ _ _ _ _Page 2 of 19_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DOSAGE AND ADMINISTRATION ................................................................................6 OVERDOSAGE ..................................................................................................................7 ACTION AND CLINICAL PHARMACOLOGY ..............................................................8 STORAGE AND STABILITY ............................................................................................9 SPECIAL HANDLING INSTRUCTIONS .........................................................................9 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................10 PART II: SCIENTIFIC INFORMATION ...............................................................................11 PHARMACEUTICAL INFORMATION ..........................................................................11 CLINICAL TRIALS ..........................................................................................................12 DETAILED PHARMACO 完全なドキュメントを読む